Gilead achieved positive results in the study of selective JAK1 inhibitor filgotinib for rheumatoid arthritis

recently, Gilead Sciences and Galapagos announced that they are studying selective JAK1 inhibitor filgotinib, a phase 3trial(which reaches the primary endpoint and all key secondary endpoints) in the treatment of severe active rheumatoid arthritisabout filgotinib
filgotinib, a selective JAK1 inhibitor, which can be used in the treatment of a variety of inflammatory diseases, in collaboration with Gilead Sciences and GalapagosFINCH 2 is a 24-week global, randomized, double-blind, placebo-controlled 3-phase study that assessed the efficacy and safety of filgotinib in patients with moderate lysancephaloarthritisThese patients were also given regularsynthetic(co
nventional synthetic disease-modifying anti-rheumatic drugs, csDMARDs)They did not respond well to the biologics type DMARDs (bDMARDs), in which 23.7 percent of patients were treated with three or more bDMARDsAll patients were randomly assigned (1:1:1) to receive filgotinib 100 mg, filgotinib 200 mg, or placeboThe primary endpoint is the proportion of patients who reached 20% remission (ACR20) at the American Society of Rheumatology in week 12results show that the study reached its main endpointAnd at weeks 12 and 24, the proportion of patients who reached ACR50 and ACR70, low disease activity (LDA, DAS28 (CRP) 3.2) and clinical remission (DAS28 (CRP)2.6) was significantly higher than that of the placebo group in the treatment groupin addition, filgotinib showed good tolerance in the study and had no new safety signals compared to previous trialsThe severity of adverse events and severe adverse events caused by treatment is mostly mild or moderate